Elinzanetant
Chemical compound
From Wikipedia, the free encyclopedia
Elinzanetant, sold under the brand name Lynkuet, is a medication used for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.[1] It is taken orally.[1]
EL-in-ZA-nə-tant
| |
| Clinical data | |
|---|---|
| Pronunciation | /ˌɛlɪnˈzænətænt/ EL-in-ZA-nə-tant |
| Trade names | Lynkuet |
| Other names | BAY-3427080; GSK-1144814; GSK-1144814A; NT-814 |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Oral[1] |
| Drug class | Neurokinin NK1 and NK3 receptor antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C33H35F7N4O3 |
| Molar mass | 668.657 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug acts as a selective neurokinin NK1 and NK3 receptor antagonist.[1][5]
Medical uses
Pharmacology
Pharmacodynamics
Elinzanetant has been found to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.[7][8]
History
Elinzanetant was developed by Bayer Healthcare.[1]
In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lynkuet, intended for the treatment of moderate to severe vasomotor symptoms (hot flushes).[5] The applicant for this medicinal product is Bayer AG.[5] Elinzanetant was authorized for medical use in the European Union in November 2025.[5][6]
Lynkuet was approved for medical use in the United States in October 2025.[9][10]
Society and culture
Names
Elinzanetant is the International Nonproprietary Name (INN).[11]
Elinzanetant is sold under the brand name Lynkuet.[12]
Research
In addition to approval for vasomotor symptoms, elinzanetant is under development for the treatment of sleep disorders.[13] It is in phase 2 clinical trials for this indication.[13] The drug was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.[13]
